Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern-Reference-Cited by-同舟云学术

Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern

Published:2022-06-09 Issue:7 Volume:7 Page:974-985
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Vikkurthi Rajesh,Ansari Asgar,Pai Anupama R.^ORCID,Jha Someshwar Nath,Sachan Shilpa,Pandit Suvechchha,Nikam Bhushan,Kalia Anurag,Jit Bimal Prasad,Parray Hilal Ahmad,Singh Savita,Kshetrapal Pallavi,Wadhwa Nitya,Shrivastava Tripti,Coshic Poonam,Kumar Suresh,Sharma Pragya,Sharma Nandini,Taneja Juhi,Pandey Anil K.,Sharma Ashok,Thiruvengadam Ramachandran^ORCID,Grifoni Alba^ORCID,Weiskopf Daniela,Sette Alessandro^ORCID,Bhatnagar Shinjini,Gupta Nimesh^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

Department of Biotechnology, Ministry of Science and Technology

DST | Science and Engineering Research Board

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

Link

https://www.nature.com/articles/s41564-022-01161-5.pdf

Reference53 articles.

1. Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis. 21, 950–961 (2021).